Summary of Significant Accounting Policies (Tables)

3 Months Ended

Mar. 31, 2018

Summary of Significant Accounting Policies

Schedule of weighted average shares outstanding used in calculating basic and diluted earnings per share

	Three Months Ended March 31, 2018	Three Months Ended March 31, 2017
Basic Weighted Average Shares Outstanding	51,288,424	50,686,044
Effect of Dilutive Securities	—	—
Diluted Weighted Average Shares Outstanding	51,288,424	50,686,044

Disaggregation Of Revenue

In thousands of US dollars ($)		Three Months Ended March 31, 2018
Products By Geographic Area		Total		U.S.		Rest of World
Drug Revenue Segment
License Fee – Over time	$	68	$	-	$	68
Concentrate Products
Product Sales – Point-in-time		14,376		12,472		1,904
License Fee – Point-in-time		504		504		-
Total Concentrate Products		14,880		12,976		1,904
Net Revenue	$	14,948	$	12,976	$	1,972

Contract Balances

In thousands of US dollars ($)		March 31, 2018		December 31, 2017
Receivables, which are included in ‘Trade and other receivables’	$	5,684	$	5,544
Contract liabilities	$	16,151	$	16,723